Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Sharps Technology Inc (STSS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/20/2025: STSS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $22
1 Year Target Price $22
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -24.26% | Avg. Invested days 9 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.55M USD | Price to earnings Ratio - | 1Y Target Price 22 |
Price to earnings Ratio - | 1Y Target Price 22 | ||
Volume (30-day avg) 1 | Beta 1.92 | 52 Weeks Range 3.36 - 2224.20 | Updated Date 06/29/2025 |
52 Weeks Range 3.36 - 2224.20 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1837.74 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -42.67% | Return on Equity (TTM) -75.14% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 8453556 | Price to Sales(TTM) - |
Enterprise Value 8453556 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.19 | Shares Outstanding 1019080 | Shares Floating 1017855 |
Shares Outstanding 1019080 | Shares Floating 1017855 | ||
Percent Insiders 0.06 | Percent Institutions 6.14 |
Analyst Ratings
Rating 1 | Target Price 22 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Sharps Technology Inc
Company Overview
History and Background
Sharps Technology, Inc. (STSS) was founded to commercialize innovative, cost-effective safety syringe technologies and improve global healthcare outcomes by reducing the spread of disease through injection.
Core Business Areas
- Safety Syringes: Development, manufacturing, and distribution of single-use, auto-disable safety syringes designed to prevent needlestick injuries and promote safe injection practices.
- Other Medical Devices: Potential expansion into other related medical device areas, depending on market needs and strategic partnerships.
Leadership and Structure
Details on specific leadership roles and organizational structure are not publicly available in detailed format but the information can be reviewed in public annual filings. Sharps Technology is structured with a board of directors and an executive management team.
Top Products and Market Share
Key Offerings
- Sharps Provensau2122: A line of ultra-low waste space, auto-retractable safety syringes. Market share data is not available; however, key competitors are Becton Dickinson (BDX), Smiths Medical, and Retractable Technologies (RTI). Revenue data is not available.
Market Dynamics
Industry Overview
The medical device industry is highly regulated, competitive, and driven by technological innovation. There is a growing demand for safety syringes to reduce healthcare-associated infections and needlestick injuries.
Positioning
Sharps Technology aims to be a significant player in the safety syringe market. Its competitive advantages focus on ultra-low waste and user safety.
Total Addressable Market (TAM)
The global safety syringes market is estimated to be in the billions of dollars. Sharps Technology aims to capture a substantial share of this market through its focus on cost and technological innovations.
Upturn SWOT Analysis
Strengths
- Innovative safety syringe technology
- Potential for reducing healthcare costs
- Focus on user safety
- Scalable manufacturing capabilities
Weaknesses
- Limited brand recognition
- Reliance on distribution partners
- Small market capitalization
- Unproven track record in large-scale commercialization
Opportunities
- Growing demand for safety syringes
- Expansion into new markets
- Strategic partnerships
- New product development
Threats
- Intense competition
- Regulatory changes
- Price pressure
- Technological obsolescence
Competitors and Market Share
Key Competitors
- BD (BDX)
- Retractable Technologies Inc (RTI)
- Medtronic (MDT)
Competitive Landscape
Sharps Technology's competitive advantage lies in its unique safety features. However, it faces competition from larger, well-established players with greater financial resources and market presence. Note that market share numbers are estimates due to limited data on smaller players.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited due to the company's early stage of commercialization.
Future Projections: Future growth projections are uncertain and dependent on successful commercialization, strategic partnerships, and market adoption.
Recent Initiatives: Recent initiatives include expanding manufacturing capacity and pursuing regulatory approvals.
Summary
Sharps Technology has innovative safety syringe technology and is in a growing market; however, it faces significant competition, limited brand recognition, and reliance on external partners. Successful commercialization of its products and expansion into new markets are critical for its future growth. Financial performance relies on revenue generation and cost management, so those will have to be improved for overall stability. Strategic alliances and partnerships will likely accelerate growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports (estimated)
Disclaimers:
This analysis is based on limited publicly available information and estimates. Market share data is approximate and subject to change. Investing in micro-cap stocks involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sharps Technology Inc
Exchange NASDAQ | Headquaters Melville, NY, United States | ||
IPO Launch date 2022-04-14 | CEO & Director Mr. Robert M. Hayes | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 55 | Website https://sharpstechnology.com |
Full time employees 55 | Website https://sharpstechnology.com | ||
Sharps Technology, Inc., a medical device and pharmaceutical packaging company, engages in the design, research and development, manufacturing, and commercialization of safety syringe products in the United States. The company provides safety syringe products comprising Securgard, Sologard, and Sharps Provensa that are ultra-low waste syringes for passive, and safety and reuse prevention features, as well as develops prefillable syringe systems. The company was incorporated in 2017 and is based in Melville, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.